Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...

Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal ...

CVS Health Corp.’s drug-benefits unit negotiated a deal to make Novo Nordisk A/S’s Wegovy more widely available to its ...

Novo Nordisk cut 2025 sales forecast citing competition from compounded versions of its Wegovy weight-loss drug. Invezz takes ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...

Zepbound (tirzepatide) is a prescription drug that’s used for weight loss and obstructive sleep apnea in certain adults. Zepbound comes as a liquid solution inside prefilled injection pens.

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

CVS said it will expand access to blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark.

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...